




Instance: composition-en-9601a69cc77fa33a3d0e2e4ba9d747e9
InstanceOf: CompositionUvEpi
Title: "Composition for edurant Package Leaflet"
Description:  "Composition for edurant Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9601a69cc77fa33a3d0e2e4ba9d747e9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - edurant"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What EDURANT is and what it is used for</li>
<li>What you need to know before you take EDURANT</li>
<li>How to take EDURANT</li>
<li>Possible side effects</li>
<li>How to store EDURANT</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What edurant is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What edurant is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>EDURANT contains rilpivirine that is used for the treatment of Human Immunodeficiency Virus 
(HIV) infection. It belongs to a group of HIV medicines called non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). EDURANT works by reducing the amount of HIV in your body.
EDURANT is used in combination with other HIV medicines to treat adolescents and adults 
12 years of age and older who are infected with HIV and who have never been treated before with 
HIV medicines.
Your doctor will discuss with you which combination of medicines is best for you.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take edurant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take edurant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take EDURANT if you are allergic to rilpivirine or any of the other ingredients of this 
medicine (listed in section 6).
Do not take EDURANT in combination with any of the following medicines as they may affect the 
way EDURANT or the other medicine works:
-
carbamazepine, oxcarbazepine, phenobarbital, phenytoin (medicines to treat epilepsy and 
prevent seizures)
-
rifampicin, rifapentine (medicines to treat some bacterial infections such as tuberculosis)
-
omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, (proton pump inhibitors 
that are medicines to prevent and treat stomach ulcers, heartburn or acid reflux disease)
-
dexamethasone (a corticosteroid used in a variety of conditions such as inflammation and 
allergic reactions) when taken by mouth or injected, except as a single dose treatment
-
products that contain St John s wort (Hypericum perforatum) (a herbal product used for 
depression).
If you are taking any of the above, ask your doctor about alternatives.
Warnings and precautions
Talk to your doctor or pharmacist before taking EDURANT.
EDURANT is not a cure for HIV infection. It is part of a treatment reducing the amount of virus in the 
blood. 
EDURANT has only been used in a limited number of patients of 65 years or older. If you belong to 
this age group, please discuss the use of EDURANT with your doctor.
Tell your doctor about your situation
Make sure that you check the following points and tell your doctor if any of these apply to you.
-
Tell your doctor if you have or have had problems with your liver, including 
hepatitis B and/or C, and/or problems with your kidneys. Your doctor may evaluate how 
severe your liver or kidney disease is before deciding if you can take EDURANT.
-
Tell your doctor immediately if you notice any symptoms of infections (for example, fever, 
chills, sweats). In some patients with advanced HIV infection and a history of opportunistic
infection, signs and symptoms of inflammation from previous infections may occur soon after 
HIV treatment is started. It is believed that these symptoms are due to an improvement in the 
body s immune response, enabling the body to fight infections that may have been present with 
no obvious symptoms.
-
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when 
the immune system attacks healthy body tissue) may also occur after you start taking medicines 
for the treatment of your HIV infection. Autoimmune disorders may occur many months after 
the start of treatment. If you notice any symptoms of infection or other symptoms such as 
muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of 
the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek 
necessary treatment.
-
Tell your doctor if you are taking any medicines that may cause a life-threatening irregular 
heartbeat (Torsade de Pointes).
Children
EDURANT is not for use in children less than 12 years of age, because it has not been sufficiently 
studied in these patients.
Other medicines and EDURANT
You must take EDURANT together with other HIV medicines. Your doctor will advise on which HIV 
medicines can be combined with EDURANT and together you will decide which combination fits 
your needs best. Follow your doctor s instruction carefully.
Some medicines may affect the levels of EDURANT in the blood when they are taken at the same 
time as EDURANT.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.
It is not recommended to combine EDURANT with other non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) such as delavirdine, efavirenz, etravirine, and nevirapine.
The effects of EDURANT or other medicines might be influenced if you take EDURANT together 
with any of the following medicines. Tell your doctor if you take:
-
rifabutin (a medicine to treat some bacterial infections). If you take this medicine while taking 
EDURANT, please carefully read how to take EDURANT in section 3  Instructions for proper 
use in adults and adolescents (12 to less than 18 years of age) .
-
clarithromycin, erythromycin (antibiotics)
-
cimetidine, famotidine, nizatidine, ranitidine (H2-receptor antagonists used to treat stomach or 
intestinal ulcers or used to relieve heartburn due to acid reflux). If you take these medicines, 
please carefully read how to take them in section 3  Instructions for proper use in adults and 
adolescents (12 to less than 18 years of age) .
-
antacids (used to treat diseases related to the acid in the stomach; for example, 
aluminium/magnesium hydroxide, calcium carbonate). If you take these medicines, please 
carefully read how to take them in section 3  Instructions for proper use in adults and 
adolescents (12 to less than 18 years of age) .
-
methadone (used to treat narcotic withdrawal and dependence)
-
dabigatran etexilate (anticoagulant).
Pregnancy and breast-feeding
Tell your doctor immediately if you are pregnant or if you plan to become pregnant. Pregnant women 
should discuss the use of EDURANT with their doctor.
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed 
on to the baby in breast milk.
If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as 
soon as possible.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Some patients may experience tiredness, dizziness or drowsiness during treatment with EDURANT. 
Do not drive or operate machinery if you feel tired, dizzy or drowsy while taking EDURANT.
EDURANT contains lactose
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor 
before taking this medicine.
EDURANT contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free .</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take edurant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take edurant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.
Instructions for proper use in adults and adolescents (12 to less than 18 years of age)
The recommended dose of EDURANT is one tablet once a day.
EDURANT must be taken with a meal. A meal is important to get the right levels of active 
substance in your body. A nutritional drink (e.g. protein-rich) alone does not replace a meal.
There are four situations that require special attention:
1. If you take rifabutin (a medicine to treat some bacterial infections), take two tablets of 
EDURANT once a day. When you stop taking rifabutin, take one tablet of EDURANT once a 
day. Talk to your doctor or pharmacist if you are not sure.
2. If you take an antacid (a medicine to treat diseases related to the acid in the stomach such as 
aluminium / magnesium hydroxide, calcium carbonate). Take the antacid either at least 2 hours 
before or at least 4 hours after EDURANT (see section 2  Other medicines and EDURANT ).
3. If you take an H2-receptor antagonist (medicines used to treat stomach or intestinal ulcers or 
used to relieve heartburn due to acid reflux (such as cimetidine, famotidine, nizatidine or 
ranitidine). Take the H2-receptor antagonist at least 12 hours before or at least 4 hours after 
EDURANT (see section 2  Other medicines and EDURANT ). H2-receptor antagonists should 
not be taken in a twice a day regimen. Talk to your doctor about an alternative regimen.
4. If you take didanosine (a medicine to treat HIV infection), no dose adjustment is required. 
Didanosine should be administered on an empty stomach at least two hours before or at least 
four hours after EDURANT (which must be taken with a meal).
Removing the child resistant cap
The bottle comes with a child resistant cap. It can be opened by pushing the screw 
cap down while turning it anti-clockwise.
If you take more EDURANT than you should
Contact your doctor or pharmacist immediately. In case of overdose, you may have a headache, 
nausea, dizziness, and/or abnormal dreams.
If you forget to take EDURANT
If you notice within 12 hours of the time you usually take EDURANT, you must take the tablet as 
soon as possible. The EDURANT tablet must be taken with a meal. Then take the next dose as usual. 
If you notice after 12 hours, then skip that dose and take the next doses as usual.
Do not take a double dose to make up for a forgotten dose.
If you vomit less than 4 hours after taking EDURANT, take another tablet with a meal. If you vomit 
more than 4 hours after taking EDURANT you do not need to take another tablet until your next 
regularly scheduled tablet.
Contact your doctor if uncertain about what to do if you miss a dose or vomit.
Do not stop using EDURANT
HIV treatment does not cure HIV infection! Do not stop using EDURANT without talking to your 
doctor first. Even if you feel better, do not stop taking EDURANT or your other HIV medicines. 
Doing so could increase the risk of the virus developing resistance. Talk to your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common:
-
headache
-
nausea
-
difficulty falling asleep (insomnia)
-
dizziness
-
changes in one of your routine liver tests (transaminase)
-
increase in cholesterol and/or pancreatic amylase in your blood
Common:
-
abnormal dreams
-
rash
-
stomach pain
-
depression
-
tiredness
-
vomiting
-
drowsiness
-
decreased appetite
-
sleep disorders
-
stomach discomfort
-
depressed mood
-
dry mouth
-
low white blood cell and/or platelet count, decrease in haemoglobin in your blood, increase in 
triglycerides, lipase and/or bilirubin in your blood
Uncommon:
-
signs or symptoms of inflammation or infection, for example fever, chills, sweats (immune 
reactivation syndrome)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store edurant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store edurant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the bottle after 
EXP. The expiry date refers to the last day of that month.
Store in the original bottle in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What EDURANT contains</h2>
<p>The active substance is rilpivirine in the form of rilpivirine hydrochloride. Each tablet of 
EDURANT contains rilpivirine hydrochloride equivalent to 25 mg rilpivirine.
-
The other ingredients of the film-coated tablet core are lactose monohydrate, croscarmellose 
sodium, povidone K30, polysorbate 20, silicified microcrystalline cellulose and magnesium 
stearate. The film-coating contains lactose monohydrate, hypromellose 2910 6 mPa.s, titanium 
dioxide E171, macrogol 3000 and triacetin.
What EDURANT looks like and contents of the pack
White to off-white, film-coated, round, biconvex tablet, with  TMC  on one side and  25  on the 
other side.
A bottle with child resistant closure containing 30 film-coated tablets.
Marketing Authorisation Holder
Janssen-Cilag International NV
Turnhoutseweg B-2340 Beerse
Belgium
Manufacturer
Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
04100 Latina
Italy
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
Janssen-Cilag NV
Tel/T l: +32 14 64 94 janssen@jacbe.jnj.com
Lietuva
UAB "JOHNSON &amp; JOHNSON"
Tel: +370 5 278 68 lt@its.jnj.com</p>
<p>&amp;    <br />
 .: +359 2 489 94 jjsafety@its.jnj.com
Luxembourg/Luxemburg
Janssen-Cilag NV
T l/Tel: +32 14 64 94 janssen@jacbe.jnj.com
 esk  republika
Janssen-Cilag s.r.o.
Tel: +420 227 012 Magyarorsz g
Janssen-Cilag Kft.
Tel.: +36 1 884 2Danmark
Janssen-Cilag A/S
Tlf: +45 4594 8jacdk@its.jnj.com
Malta
AM MANGION LTD.
Tel: +356 2397 6Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 jancil@its.jnj.com
Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1janssen@jacnl.jnj.com
Eesti
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Tel: +372 617 7ee@its.jnj.com
Norge
Janssen-Cilag AS
Tlf: +47 24 12 65 jacno@its.jnj.com</p>
<p>Janssen-Cilag    . . . .
T : +30 210 80 90  sterreich
Janssen-Cilag Pharma GmbH
Tel: +43 1 610 Espa a
Janssen-Cilag, S.A.
Tel: +34 91 722 81 infojaces@its.jnj.com
Polska
Janssen-Cilag Polska Sp. z o.o.
Tel.: +48 22 237 60 France
Janssen-Cilag
T l: 0 800 25 50 75 / +33 1 55 00 40 medisource@its.jnj.com
Portugal
Janssen-Cilag Farmac utica, Lda.
Tel: +351 214 368 Hrvatska
Johnson &amp; Johnson S.E. d.o.o.
Tel: +385 1 6610 jjsafety@JNJCR.JNJ.com
Rom nia
Johnson &amp; Johnson Rom nia SRL
Tel: +40 21 207 1Ireland
Janssen Sciences Ireland UC
Tel: +353 1 800 709 Slovenija
Johnson &amp; Johnson d.o.o.
Tel: +386 1 401 18 Janssen_safety_slo@its.jnj.com
 sland
Janssen-Cilag AB
c/o Vistor hf
S mi: +354 535 7janssen@vistor.is
Slovensk  republika
Johnson &amp; Johnson s.r.o.
Tel: +421 232 408 Italia
Janssen-Cilag SpA
Tel: 800.688.777 / +39 02 2510 1
janssenita@its.jnj.com
Suomi/Finland
Janssen-Cilag Oy
Puh/Tel: +358 207 531 jacfi@its.jnj.com</p>
<p>: +357 22 207 Sverige
Janssen-Cilag AB
Tfn: +46 8 626 50 jacse@its.jnj.com
Latvija
UAB "JOHNSON &amp; JOHNSON" fili le Latvij 
Tel: +371 678 93lv@its.jnj.com
United Kingdom (Northern Ireland)
Janssen Sciences Ireland UC
Tel: +44 1 494 567 This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-9601a69cc77fa33a3d0e2e4ba9d747e9
InstanceOf: CompositionUvEpi
Title: "Composition for edurant Package Leaflet"
Description:  "Composition for edurant Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9601a69cc77fa33a3d0e2e4ba9d747e9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - edurant"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Se den nyeste indlægsseddel på www.indlaegsseddel.dk</p>         </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen:
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage EDURANT
3. Sådan skal du tage EDURANT
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What edurant is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What edurant is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>EDURANT indeholder rilpivirin, der anvendes til behandling af hiv-infektion (dvs. smitte med 
humant immundefektvirus). Det tilhører en gruppe af hiv-medicin, som kaldes non-nukleosid reverse
transcriptasehæmmere (NNRTI). EDURANT virker ved at reducere mængden af hiv-virus i kroppen.
EDURANT anvendes sammen med andre former for hiv-medicin til behandling af voksne og unge 
over 12 år med hiv-infektion, som aldrig tidligere har fået behandling med hiv-medicin.
Lægen vil tale med dig om, hvilken kombination af lægemidler der er bedst for dig.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take edurant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take edurant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke EDURANT, hvis du er allergisk over for rilpivirin eller et af de øvrige indholdsstoffer i 
EDURANT (angivet i punkt 6).
Tag ikke EDURANT i kombination med et af følgende lægemidler, da de kan påvirke virkningen 
af EDURANT eller den anden medicin:
-
carbamazepin, oxcarbazepin, phenobarbital, phenytoin (medicin til behandling af epilepsi og til 
forebyggelse af krampeanfald).
-
rifampicin, rifapentin (medicin til behandling af visse infektioner, der skyldes bakterier, såsom 
tuberkulose).
-
omeprazol, esomeprazol, lansoprazol, pantoprazol, rabeprazol (syrepumpehæmmere) (medicin 
til forebyggelse og behandling af mavesår, halsbrand eller tilbageløb af mavesyre).
-
dexamethason (et kortikosteroid, som bruges til behandling af mange forskellige tilstande, f.eks. 
betændelse og allergiske reaktioner), når det tages gennem munden eller som indsprøjtning, 
bortset fra som enkeltdosis.
-
produkter, som indeholder perikon (Hypericum perforatum) (et naturlægemiddel, som anvendes 
mod depression).
Spørg lægen, om du bør have anden medicin, hvis du tager et af disse lægemidler.
33
Advarsler og forsigtighedsregler
Kontakt lægen eller apotekspersonalet, før du tager EDURANT.
EDURANT kan ikke kurere hiv-infektionen. Det er en del af en behandling, som reducerer 
virusmængden i blodet.
EDURANT er kun blevet anvendt til et begrænset antal patienter over 65 år. Hvis du tilhører denne 
aldersgruppe, skal du tale med lægen om, hvorvidt du kan tage EDURANT.
Fortæl lægen om din situation
Læs følgende punkter, og fortæl det til lægen, hvis nogen af dem gælder for dig.
-
Fortæl det til lægen, hvis du har eller har haft leverproblemer, herunder hepatitis B og/eller C 
(leverbetændelse) og/eller nyreproblemer. Lægen vil vurdere, hvor alvorlig din lever- eller 
nyresygdom er, før vedkommende beslutter, om du kan tage EDURANT.
-
Fortæl det straks til lægen, hvis du mærker symptomer på infektion (f.eks. feber, 
kulderystelser, svedeture). Hos nogle patienter med fremskreden hiv-infektion, som tidligere har 
haft opportunistiske infektioner (dvs. infektioner, som raske mennesker er modstandsdygtige 
over for, og som kun angriber mennesker med nedsat immunforsvar), kan tegn og symptomer på 
betændelse fra tidligere infektioner vise sig kort efter påbegyndelse af hiv-behandling. Disse 
symptomer skyldes formodentlig en bedring i kroppens immunforsvar, som sætter kroppen i 
stand til at bekæmpe infektioner, der har været til stede i kroppen uden at give synlige 
symptomer.
-
Ud over de opportunistiske infektioner kan autoimmune lidelser (skyldes, at immunsystemet 
angriber sundt kropsvæv) også opstå, efter du er begyndt at tage medicin til behandling af din 
hiv-infektion. Autoimmune lidelser kan opstå mange måneder efter, du er påbegyndt 
behandling. Du skal straks informere din læge for at få den nødvendige behandling, hvis du 
bemærker symptomer på infektion eller andre symptomer, såsom muskelsvaghed, svaghed 
begyndende i hænder og fødder, og som bevæger sig op igennem kroppen, hjertebanken, rysten 
eller hyperaktivitet.
-
Fortæl det til lægen, hvis du tager lægemidler, der kan give livstruende uregelmæssig 
hjerterytme (torsades de pointes).
Børn
EDURANT er ikke beregnet til børn under 12 år, da det ikke er undersøgt tilstrækkeligt hos disse 
patienter.
Brug af anden medicin sammen med EDURANT
Du skal tage EDURANT sammen med anden hiv-medicin. Lægen vil rådgive dig om, hvilken 
hiv-medicin du kan kombinere med EDURANT, så I sammen kan finde frem til den kombination, der 
bedst dækker dine behov. Følg lægens anvisninger omhyggeligt.
Nogle former for medicin kan påvirke niveauet af EDURANT i blodet, når de samtidig tages med 
EDURANT.
Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig.
EDURANT bør ikke kombineres med andre non-nukleosid reverse transcriptasehæmmere (NNRTI) 
såsom delavirdin, efavirenz, etravirin og nevirapin.
Virkningen af EDURANT eller af anden medicin kan blive påvirket, hvis du tager EDURANT
sammen med nedenstående medicin. Fortæl det til lægen, hvis du tager:
-
rifabutin (medicin til behandling af visse infektioner, der skyldes bakterier). Hvis du tager 
rifabutin samtidig med EDURANT, skal du sætte dig grundigt ind i afsnittet i pkt. 3 om,
hvordan du skal tage EDURANT: "Vejledning i brug til voksne og unge (fra 12 til 
under 18 år)".
-
clarithromycin, erythromycin (antibiotika).
34
-
cimetidin, famotidin, nizatidin, ranitidin (H2-receptorantagonister til behandling af mavesår eller 
sår på tarmen eller til lindring af halsbrand, der skyldes tilbageløb af syre). Hvis du tager disse 
former for medicin, skal du omhyggeligt læse, hvordan du skal tage dem, i pkt. 3 "Vejledning i
brug til voksne og unge (fra 12 til under 18 år)".
-
antacida (bruges til behandling af sygdomme forårsaget af for meget mavesyre; f.eks. 
aluminium-/magnesiumhydroxid, calciumcarbonat). Hvis du tager disse former for medicin, 
skal du omhyggeligt læse, hvordan du skal tage dem, i pkt. 3 "Vejledning i brug til voksne og 
unge (fra 12 til under 18 år)".
-
methadon (anvendes i forbindelse med nedtrapning eller afhængighed af narkotika).
-
dabigatranetexilat (hindrer blodet i at størkne).
Graviditet og amning
Fortæl det straks til lægen, hvis du er gravid eller planlægger at blive gravid. Hvis du er gravid, skal du 
spørge din læge til råds vedrørende brugen af EDURANT.
Amning anbefales ikke hos kvinder, der er hiv-positive, da hiv-infektion kan overføres til barnet 
gennem modermælken.
Hvis du ammer eller påtænker at amme, bør du drøfte det med lægen hurtigst muligt.
Spørg din læge eller apoteket til råds, før du tager nogen form for medicin.
Trafik- og arbejdssikkerhed
Nogle patienter kan blive trætte, svimle eller sløve under behandlingen med EDURANT. Undlad at 
køre eller betjene maskiner, hvis du føler dig træt, svimmel eller sløv, mens du tager EDURANT.
EDURANT indeholder lactose
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter.
EDURANT indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take edurant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take edurant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet.
Vejledning i brug til voksne og unge (fra 12 til under 18 år)
Den sædvanlige dosis af EDURANT er én tablet dagligt.
EDURANT skal tages i forbindelse med et måltid. Måltidet er vigtigt, for at du kan få det rette 
niveau af det aktive stof i kroppen. En ernæringsdrik (f.eks. en proteindrik) alene kan ikke erstatte et 
måltid.
Fire situationer kræver særlig opmærksomhed:
1. Hvis du tager ribabutin (medicin til behandling af visse infektioner, der skyldes bakterier): 
Tag to tabletter EDURANT en gang dagligt. Når du stopper med at tage rifabutin, skal du kun 
tage én tablet EDURANT en gang dagligt. Tal med din læge eller apotekspersonalet, hvis du er i 
tvivl.
2. Hvis du tager et antacidum (medicin, der bruges til behandling af sygdomme, der forbindes 
med mavesyre; f.eks. aluminium-/magnesiumhydroxid, calciumcarbonat). Tag medicinen enten 
mindst 2 timer før eller mindst 4 timer efter EDURANT (se "Brug af anden medicin sammen 
med EDURANT" under pkt. 2).
3. Hvis du tager en H2-receptorantagonist (medicin, der bruges til behandling af mavesår eller 
sår på tarmen eller til lindring af halsbrand, der skyldes tilbageløb af syre (f.eks. cimetidin, 
35
famotidin, nizatidin eller ranitidin)). Tag H2-receptorantagonisten mindst 12 timer før eller 
mindst 4 timer efter EDURANT (se "Brug af anden medicin sammen med EDURANT" under
pkt. 2). H2-receptorantagonister bør ikke tages to gange dagligt. Spørg lægen, om du kan 
anvende et andet doseringsmønster.
4. Hvis du tager didanosin (medicin til behandling af hiv-infektion), er der ikke behov for 
justering af dosis. Didanosin skal tages på tom mave mindst to timer før eller mindst fire timer 
efter EDURANT (som skal tages sammen med et måltid).
Sådan fjernes det børnesikre låg
Beholderen er forsynet med et børnesikret låg. Det kan åbnes ved at trykke 
skruelåget ned, samtidig med at det drejes mod uret.
Hvis du har taget for meget EDURANT
Kontakt straks lægen eller apoteket. Hvis du har taget for mange tabletter, kan du få hovedpine, 
kvalme, svimmelhed og/eller unormale drømme.
Hvis du har glemt at tage EDURANT
Hvis du bemærker det inden for 12 timer efter det tidspunkt, hvor du normalt tager EDURANT,
skal du tage tabletten snarest muligt. EDURANT-tabletten skal tages i forbindelse med et måltid. 
Herefter skal du blot fortsætte med den sædvanlige dosis. Hvis du bemærker det efter 12 timer, skal 
du springe denne dosis over og derefter blot fortsætte med den sædvanlige dosis. Du må ikke tage en 
dobbeltdosis som erstatning for den glemte dosis.
Hvis du kaster op mindre end 4 timer efter, at du har taget EDURANT, skal du tage en tablet til 
sammen med et måltid. Hvis du kaster op over 4 timer efter, at du har taget EDURANT, behøver du 
ikke at tage en tablet, før du skal tage den næste dosis til sædvanlig tid.
Tal med lægen, hvis du er i tvivl om, hvad du skal gøre, hvis du har glemt en dosis eller kastet op.
Du må ikke holde op med at tage EDURANT
Hiv-behandling kurerer ikke hiv-infektionen! Du må ikke holde op med at tage EDURANT uden først 
at tale med lægen. Selv om du har det bedre, må du ikke holde op med at tage EDURANT eller din 
anden hiv-medicin. Hvis du gør det, øges risikoen for, at virussen udvikler resistens. Tal med lægen 
først.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Meget almindelige:
-
hovedpine
-
kvalme
-
vanskelighed ved at falde i søvn (søvnløshed)
-
svimmelhed
-
ændringer i resultatet af dine rutinemæssige leverprøver (aminotransferaser)
-
stigning i blodets indhold af kolesterol og/eller pancreas-amylase
Almindelige:
-
unormale drømme
-
udslæt
36
-
mavesmerter
-
depression
-
træthed
-
opkastning
-
sløvhed
-
nedsat appetit
-
søvnforstyrrelser
-
mavegener
-
dårligt humør
-
mundtørhed
-
lavt antal hvide blodlegemer og/eller blodplader, fald i blodets indhold af hæmoglobin, stigning 
i blodets indhold af triglycerider, lipase og/eller bilirubin
Ikke almindelige:
-
symptomer på betændelsestilstand eller infektion, f.eks. feber, kulderystelser, svedeture
(immunreaktiveringssyndrom)
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store edurant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store edurant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned.
Opbevares i den originale beholder for at beskytte mod lys.
Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>EDURANT indeholder:</h2>
<p>Aktivt stof: rilpivirin i form af rilpivirinhydrochlorid. Hver EDURANT tablet indeholder 
rilpivirinhydrochlorid svarende til 25 mg rilpivirin.
-
Øvrige indholdsstoffer i den filmovertrukne tabletkerne: lactosemonohydrat, 
croscarmellosenatrium, povidon K30, polysorbat 20, silicificeret mikrokrystallinsk cellulose og 
magnesiumstearat. Filmovertrækket indeholder lactosemonohydrat, hypromellose 2910 6 mPa.s, 
titandioxid E171, macrogol 3000 og triacetin.
Udseende og pakningsstørrelser
Hvide til offwhite, filmovertrukne, runde, bikonvekse tabletter præget med "TMC" på den ene side og 
"25" på den anden side.
En beholder med børnesikret lukning, der indeholder 30 filmovertrukne tabletter.
Indehaver af markedsføringstilladelsen
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
37
Belgien
Fremstiller
Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
04100 Latina
Italien
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Janssen-Cilag NV
Tel/Tél: +32 14 64 94 11
janssen@jacbe.jnj.com
Lietuva
UAB "JOHNSON &amp; JOHNSON"
Tel: +370 5 278 68 88
lt@its.jnj.com
България
„Джонсън &amp; Джонсън България" ЕООД
Тел.: +359 2 489 94 00
jjsafety@its.jnj.com
Luxembourg/Luxemburg
Janssen-Cilag NV
Tél/Tel: +32 14 64 94 11
janssen@jacbe.jnj.com
Česká republika
Janssen-Cilag s.r.o.
Tel: +420 227 012 227
Magyarország
Janssen-Cilag Kft.
Tel.: +36 1 884 2858
Danmark
Janssen-Cilag A/S
Tlf: +45 4594 8282
jacdk@its.jnj.com
Malta
AM MANGION LTD.
Tel: +356 2397 6000
Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 955
jancil@its.jnj.com
Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1111
janssen@jacnl.jnj.com
Eesti
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Tel: +372 617 7410
ee@its.jnj.com
Norge
Janssen-Cilag AS
Tlf: +47 24 12 65 00
jacno@its.jnj.com
Ελλάδα
Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε.
Tηλ: +30 210 80 90 000
Österreich
Janssen-Cilag Pharma GmbH
Tel: +43 1 610 300
España
Janssen-Cilag, S.A.
Tel: +34 91 722 81 00
infojaces@its.jnj.com
Polska
Janssen-Cilag Polska Sp. z o.o.
Tel.: +48 22 237 60 00
France
Janssen-Cilag
Tél: 0 800 25 50 75 / +33 1 55 00 40 03
medisource@its.jnj.com
Portugal
Janssen-Cilag Farmacêutica, Lda.
Tel: +351 214 368 600
38
Hrvatska
Johnson &amp; Johnson S.E. d.o.o.
Tel: +385 1 6610 700
jjsafety@JNJCR.JNJ.com
România
Johnson &amp; Johnson România SRL
Tel: +40 21 207 1800
Ireland
Janssen Sciences Ireland UC
Tel: +353 1 800 709 122
Slovenija
Johnson &amp; Johnson d.o.o.
Tel: +386 1 401 18 00
Janssen_safety_slo@its.jnj.com
Ísland
Janssen-Cilag AB
c/o Vistor hf
Sími: +354 535 7000
janssen@vistor.is
Slovenská republika
Johnson &amp; Johnson s.r.o.
Tel: +421 232 408 400
Italia
Janssen-Cilag SpA
Tel: 800.688.777 / +39 02 2510 1
janssenita@its.jnj.com
Suomi/Finland
Janssen-Cilag Oy
Puh/Tel: +358 207 531 300
jacfi@its.jnj.com
Κύπρος
Βαρνάβας Χατζηπαναγής Λτδ
Τηλ: +357 22 207 700
Sverige
Janssen-Cilag AB
Tfn: +46 8 626 50 00
jacse@its.jnj.com
Latvija
UAB "JOHNSON &amp; JOHNSON" filiāle Latvijā
Tel: +371 678 93561
lv@its.jnj.com
United Kingdom (Northern Ireland)
Janssen Sciences Ireland UC
Tel: +44 1 494 567 444
Denne indlægsseddel blev senest ændret{ MM/ÅÅÅÅ }
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu/.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-9601a69cc77fa33a3d0e2e4ba9d747e9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for edurant Package Leaflet for language en"
Description: "ePI document Bundle for edurant Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-9601a69cc77fa33a3d0e2e4ba9d747e9"
* entry[0].resource = composition-en-9601a69cc77fa33a3d0e2e4ba9d747e9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9601a69cc77fa33a3d0e2e4ba9d747e9"
* entry[=].resource = mp9601a69cc77fa33a3d0e2e4ba9d747e9
                            
                    
Instance: bundlepackageleaflet-da-9601a69cc77fa33a3d0e2e4ba9d747e9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for edurant Package Leaflet for language da"
Description: "ePI document Bundle for edurant Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-9601a69cc77fa33a3d0e2e4ba9d747e9"
* entry[0].resource = composition-da-9601a69cc77fa33a3d0e2e4ba9d747e9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9601a69cc77fa33a3d0e2e4ba9d747e9"
* entry[=].resource = mp9601a69cc77fa33a3d0e2e4ba9d747e9
                            
                    



Instance: mp9601a69cc77fa33a3d0e2e4ba9d747e9
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product EDURANT 25 mg film-coated tablets"
Description: "EDURANT 25 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/11/736/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "EDURANT 25 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 9601a69cc77fa33a3d0e2e4ba9d747e9ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "edurant"

* status = #current
* mode = #working

* title = "List of all ePIs associated with edurant"

* subject = Reference(mp9601a69cc77fa33a3d0e2e4ba9d747e9)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#edurant "edurant"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-9601a69cc77fa33a3d0e2e4ba9d747e9) // edurant en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-9601a69cc77fa33a3d0e2e4ba9d747e9) // edurant da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-9601a69cc77fa33a3d0e2e4ba9d747e9
InstanceOf: List

* insert 9601a69cc77fa33a3d0e2e4ba9d747e9ListRuleset
    